Medical students' exposure to pharmaceutical industry marketing: A survey at one U.S. medical school

Academic Medicine

Volumn 79, Issue 11, 2004, Pages 1041-1045

  Bellin, Melena ^a,b   McCarthy, Susan ^a,b   Drevlow, Laurel ^c   Pierach, Claus ^c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c ABBOTT NORTHWESTERN HOSPITAL   (United States)

^d Univ of MN Med Sch Twin Cities

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; DRUG INDUSTRY; DRUG MARKETING; FEMALE; HEALTH CARE INDUSTRY; HEALTH SURVEY; HUMAN; MALE; MEDICAL EDUCATION; MEDICAL PROFESSION; MEDICAL SCHOOL; MEDICAL SOCIETY; MEDICAL STUDENT; OUTCOMES RESEARCH; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RESIDENCY EDUCATION; RESIDENT; REVIEW; TEACHING HOSPITAL; UNITED STATES;

EID: 13644261461     PISSN: 10402446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001888-200411000-00005     Document Type: Review

References (20)

1. Zuger A. Fever pitch: getting doctors to prescribe is big business. New York Times. 1999 Jan 11; Sect A:1 (col 4).
2. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ. 1993;149:1401-7.
3. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-80.
4. Madhavan S, Amonkar MM, Elliott D, Burke K, Gore P. The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians. J Clin Pharm Ther. 1997;22:207-15.
5. Lichstein PR, Turner RC, O'Brien K. Impact of pharmaceutical company representatives on internal medicine residency programs: a survey of residency program directors. Arch Intern Med. 1992;152:1009-13.
6. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers: interactions with faculty and housestaff. J Gen Intern Med. 1990;5:240-3.
7. Sigworth SK, Nettleman MD, Cohen GM. Pharmaceutical branding of resident physicians [letter]. JAMA. 2001;286:1024-5.
8. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA. 1990;264:1693-8.
9. Stienman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551-7.
10. Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products. Acad Med. 1997;72:916-8.
11. Vinson DC, McCandless B, Hosokawa MC. Medical students' attitudes toward pharmaceutical marketing: possibilities for change. Fam Med. 1993;25:31-3.
12. Chren MM, Landefeld CS, Murray TH. Doctors, drug companies, and gifts. JAMA. 1989;262:3448-51.
13. Banks JW, Mainous AG. Attitudes of medical school faculty towards gifts from pharmaceutical industry. Acad Med. 1992;67:610-2.
14. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684-9.
15. Brotzman GL, Mark DH. Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract. 1992;34:54-7.
16. American Medical Association, Resident Physicians Section. Guidelines for interactions with pharmaceutical companies. JAMA. 1993;270:1250.
17. House of Delegates, American Medical Student Association. AMSA policy on pharmaceutical promotions. Available at http://www.amsa.org/ prof/policy.cfm. Accessed January 14, 2003.
18. Brotzman GL, Mark DH. The effect of resident attitudes on regulatory policies regarding pharmaceutical representative activities. J Gen Intern Med. 1993;8:130-4.
19. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post-training attitudes and behavior. JAMA. 2001;286:1994-9.
20. Rehnquist J, Department of Health and Human Services, Office of Inspector General. OIG compliance program guidelines for pharmaceutical manufacturers. Federal Register. 2003;68:23731-43.